AXT 1005
Alternative Names: AXT-1005Latest Information Update: 28 Aug 2023
At a glance
- Originator Novartis
- Developer Axter Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 10 Aug 2023 Preclinical trials in Acute myeloid leukaemia in China (unspecified route), prior to August 2023 (Axter Therapeutics pipeline, August 2023)
- 10 Aug 2023 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route), prior to August 2023 (Axter Therapeutics pipeline, August 2023)
- 10 Aug 2023 Preclinical trials in Solid tumours in China (unspecified route), prior to August 2023 (Axter Therapeutics pipeline, August 2023)